Accessibility Menu
Alterity Therapeutics logo

Alterity Therapeutics(NASDAQ) ATHE

Market Cap$83.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-99%
5 Year-67%
1 Year-12%
1 Month+1%
$4.53
+0.11%
+0.01Today
Alterity Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.522026-09-02
Alterity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.44%USD 4.782026-08-26
1 month+1.42%USD 4.462026-08-03
3 month+15.9%USD 3.902026-06-04
Year to date+46.75%USD 3.082025-12-31
1 year-12.4%USD 5.162025-09-02
3 year+63.47%USD 2.772023-09-01
5 year-67.25%USD 13.802021-09-03
Since inception-99.33%USD 678.002002-09-05

Alterity Therapeutics Financials at a Glance

Market Cap

$83.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.44M

Net Income (TTM)

-A$35.57M

EPS (TTM)

-$0.90

P/E Ratio

-5.00

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$4.53

Volume

9,465.515

Open

$4.55

Previous Close

$4.52

Daily Range

$4.53 - $4.72

52-Week Range

$2.66 - $5.89

Estimated Earnings Date

Mar 4, 2027

ATHE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterity Therapeutics

Alterity Therapeutics Limited is an Australian biopharmaceutical company dedicated to developing innovative drug treatments for neurological disorders, including Alzheimer's, Huntington's, and Parkinson's diseases. The company is advancing its lead therapy, ATH434, which has completed Phase I clinical trials for Parkinson's disease, and PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.

Products and Services
  • ATH434: Targeting Parkinson's disease with promising Phase I trial results
  • PBT2: A compound in Phase IIa trials for Alzheimer's disease
  • Focus on novel drug treatments for various neurological disorders
Growth Outlook
  • Strong pipeline with two lead candidates in advanced clinical stages
  • Significant market potential in the growing neurological disorder sector
  • Established operations in Melbourne, enhancing research and development capabilities
Financial Highlights
  • Recent quarterly revenue of AUD 1,900,724, showing growth potential
  • Cash and cash equivalents of AUD 49,151,738, providing operational stability
  • Current ratio of 21.98, indicating strong liquidity position
Alterity Therapeutics Limited is positioned in the biotechnology sector, focusing on critical neurological conditions that affect millions globally. The company's innovative approach to drug development, particularly with ATH434 and PBT2, highlights its commitment to addressing unmet medical needs. The financial metrics indicate a solid cash position, which supports ongoing research and development efforts. With a strong pipeline and a favorable market outlook, Alterity Therapeutics presents an intriguing opportunity for investors interested in the biopharmaceutical landscape.
AI Generated • Aug 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

David A. Stamler, MD

Website

www.alteritytherapeutics.com

Headquarters

Melbourne, VIC 3000, AU

ATHE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-48.25%

Return on Capital

-64.77%

Return on Assets

-50.85%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$83.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.39M

Volume

9.47K

Avg. Volume

43.50K

Financials (TTM)

Gross Profit

A$5.20M

Operating Income

-A$42.97M

EBITDA

-A$42.92M

Operating Cash Flow

-A$33.94M

Capital Expenditure

A$23.22M

Free Cash Flow

-A$10.71M

Cash & ST Invst.

A$37.32M

Total Debt

A$193.48K

Alterity Therapeutics Performance Analysis

Alterity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Alterity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-24.2%
Q42025-06-30138.7%
Q22025-12-31-100.0%
Q42026-06-30N/A
Alterity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -114.83-1.2%
20242024-06-30AUD -2.06-98.2%
20252025-06-30AUD -0.74-64.2%
20262026-06-30AUD -0.9022.4%
Alterity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3130.0%
Q42025-06-3050.0%
Q22025-12-31-28.6%
Q42026-06-30-44.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$58.46K

-102.9%

Gross Margin

0.00%

N/A

Market Cap

$83.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.24M

N/A

Employees

9

N/A

Net Income

-A$13.98M

-10.8%

EBITDA

-A$15.52M

-6.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$37.32M

+195.3%

Total Debt

A$193.48K

+21.6%

Accounts Receivable

A$7.70M

+90.5%

Inventory

A$0.00

N/A

Long Term Debt

A$138.30K

+166.4%

Short Term Debt

A$55.18K

-48.5%

Return on Assets

-50.85%

N/A

Return on Invested Capital

-66.30%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$12.80M

-57.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANVSAnnovis Bio, Inc.
$1.35-20.59%
GBIOGeneration Bio Co.
$5.34+0.00%
MURAMural Oncology plc
$2.04+0.00%
EVAXEvaxion Biotech A/S
$3.07+0.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.67+0.14%
SPCXSpace Exploration Technologies
$150.70+0.07%
NVDANvidia
$227.58+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.90+0.05%

Questions About ATHE

What is the current price of Alterity Therapeutics?

Alterity Therapeutics is trading at $4.53 per share.

What is the 52-week range for Alterity Therapeutics?

Over the past 52 weeks, Alterity Therapeutics has traded between $2.66 and $5.89.

How much debt does Alterity Therapeutics have?

As of the most recent reporting period, Alterity Therapeutics reported total debt of A$134.03K.

How much cash does Alterity Therapeutics have on hand?

Alterity Therapeutics reported A$25.85M in cash and cash equivalents in its most recent financial results.

What is Alterity Therapeutics’s dividend yield?

Alterity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services